2.80
-0.22(-7.28%)
Currency In USD
| Previous Close | 3.02 |
| Open | 3.09 |
| Day High | 3.09 |
| Day Low | 2.79 |
| 52-Week High | 4.97 |
| 52-Week Low | 1.75 |
| Volume | 20,127 |
| Average Volume | 59,185 |
| Market Cap | 38.41M |
| PE | -1.83 |
| EPS | -1.53 |
| Moving Average 50 Days | 2.43 |
| Moving Average 200 Days | 2.99 |
| Change | -0.22 |
If you invested $1000 in Grace Therapeutics, Inc. (GRCE) since IPO date, it would be worth $930.23 as of May 09, 2025 at a share price of $2.8. Whereas If you bought $1000 worth of Grace Therapeutics, Inc. (GRCE) shares 0 years ago, it would be worth $930.23 as of May 09, 2025 at a share price of $2.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
GlobeNewswire Inc.
Apr 09, 2025 12:00 PM GMT
NDA Submission Anticipated Q2 Calendar 2025PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 25, 2025 1:00 PM GMT
PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formu
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
GlobeNewswire Inc.
Feb 10, 2025 1:05 PM GMT
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an additional $15 million in poten